Also, CEO Joseph C. Papa bought 202,000 shares of Valeant Pharmaceuticals International stock in a transaction on Friday, June 10th.
Advertisement
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, David Risinger and David Amsellem have a total average return of -1.6% and -6.3% respectively. They now have a $42.00 target price on the specialty pharmaceutical company’s stock.
Valeant Pharmaceuticals International, Inc.is a pharmaceutical and medical device company. (NYSE:VRX) reported earning per shares for the quarter ending Aug 09 BMO at 1.4, whereas, 15 number of analysts estimated the mean EPS at 1.78. Boothbay Fund Management LLC increased its position in Valeant Pharmaceuticals International by 275.4% in the first quarter. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. Overweight rating was given by 1 analysts and Underweight rating was given by 1 analysts. The average price target of all the analysts comes to $42. Royal Bank Of Canada reissued a “sector perform” rating and issued a $33.00 target price (down previously from $58.00) on shares of Valeant Pharmaceuticals International in a report on Friday, June 3rd. They now have a United States dollars 8 price target on the stock. 0 analysts have suggested “Sell” for the company. He doesn’t mention any of the companies accused of price gouging and profiteering recently, but he’s clearly referring to Valeant Pharmaceuticals (VRX), Mylan (MYL) and Turing. They now have a United States dollars 36 price target on the stock.
The average true range of Valeant Pharmaceuticals International, Inc.’s (VRX) is recorded at 1.53 and the relative strength index of the stock stands 58.98. The heightened volatility saw the trading volume jump to 1,54,49,178 shares. The company traded as low as $6.14 on the day. The stock’s market capitalization is 10.41B. The stock’s price moved up its 200-day moving average of $9.36.
Advertisement
Shares of Valeant Pharmaceuticals are up almost 2% to $30.15 in pre-market trading. The company has shown a slight glimpse of confidence in its second quarter financial year 2016 (2QFY16). The 1 year EPS growth rate is 2.11. As a result of Merck KGaA, Darmstadt, Germany’s and the Company’s decision to cease further joint development of evofosfamide in December 2015, the Company immediately recognized all of the remaining deferred revenue into revenue during the quarter ending December 31, 2015. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). Valeant Pharmaceuticals Intl Inc makes up approx 0.01% of Tiaa Cref Investment Management’s portfolio. Valeant Pharmaceuticals International, Inc. got Upgrade on 17-Aug-16 where investment firm Morgan Stanley Upgrade the stock from Equal-Weight to Overweight.
